Fifty-four patients with chronic osteomyelitis sustained by methicillin-resistant staphylococcus were treated with daptomycin, linezolid, or teicoplanin and observed over time. Median time to CRP normalization was 7 weeks for daptomycin, 8 weeks for linezolid, and 12 weeks for teicoplanin (X2 =14.1; p < 0.001). Cure rate (intention to treat analysis) was 83% for the cases receiving teicoplanin, 77% for those receiving linezolid and 92% for those receiving daptomycin. We conclude that daptomycin and linezolid have to be considered at least equivalent to teicoplanin for the treatment of MRSA osteomyelitis.
Impact of therapeutic choices on outcome of osteomyelitis caused by MRSA / T., Ascione; M. D., Iannece; P., Rosario; R., Pempinello; P., Pagliano; M., Conte; C., Pempinello; R., Rotondo; Mariconda, Massimo; S., Lepore. - In: JOURNAL OF INFECTION. - ISSN 0163-4453. - 63:1(2011), pp. 102-104. [10.1016/j.jinf.2011.04.015]
Impact of therapeutic choices on outcome of osteomyelitis caused by MRSA
MARICONDA, MASSIMO;
2011
Abstract
Fifty-four patients with chronic osteomyelitis sustained by methicillin-resistant staphylococcus were treated with daptomycin, linezolid, or teicoplanin and observed over time. Median time to CRP normalization was 7 weeks for daptomycin, 8 weeks for linezolid, and 12 weeks for teicoplanin (X2 =14.1; p < 0.001). Cure rate (intention to treat analysis) was 83% for the cases receiving teicoplanin, 77% for those receiving linezolid and 92% for those receiving daptomycin. We conclude that daptomycin and linezolid have to be considered at least equivalent to teicoplanin for the treatment of MRSA osteomyelitis.File | Dimensione | Formato | |
---|---|---|---|
full text.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
204.17 kB
Formato
Adobe PDF
|
204.17 kB | Adobe PDF | Visualizza/Apri |
abstract.doc
accesso aperto
Tipologia:
Abstract
Licenza:
Dominio pubblico
Dimensione
26 kB
Formato
Microsoft Word
|
26 kB | Microsoft Word | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.